The estimated Net Worth of Keith Kennedy is at least $6.06 Milione dollars as of 2 July 2020. Keith Kennedy owns over 86,424 units of Veracyte Inc stock worth over $3,627,242 and over the last 8 years Keith sold VCYT stock worth over $2,437,157.
Keith has made over 7 trades of the Veracyte Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently Keith sold 86,424 units of VCYT stock worth $2,437,157 on 2 July 2020.
The largest trade Keith's ever made was selling 86,424 units of Veracyte Inc stock on 2 July 2020 worth over $2,437,157. On average, Keith trades about 6,515 units every 11 days since 2016. As of 2 July 2020 Keith still owns at least 119,632 units of Veracyte Inc stock.
You can see the complete history of Keith Kennedy stock trades at the bottom of the page.
Keith's mailing address filed with the SEC is 6000 SHORELINE COURT, SUITE 300, , SOUTH SAN FRANCISCO, CA, 94080.
Over the last 11 years, insiders at Veracyte Inc have traded over $201,983,044 worth of Veracyte Inc stock and bought 75,122 units worth $1,149,322 . The most active insiders traders include Group Holdings (Sbs) Adviso..., Nicole Vitullo e Jesse I Treu. On average, Veracyte Inc executives and independent directors trade stock every 20 days with the average trade being worth of $804,905. The most recent stock trade was executed by John Leite on 4 September 2024, trading 5,479 units of VCYT stock currently worth $163,165.
veracyte is a pioneering genomic diagnostics company. our tests are dramatically improving clinical outcomes for patients by resolving inconclusive results from traditional diagnostic methods. we ask the right questions to resolve ambiguity and bring assurance to light, rendering tens of thousands of costly and unnecessary surgeries truly unnecessary. we are giving patients a clearer path forward. through scientific rigor we employ the best tools, best science and best minds to create tests that enable a more accurate diagnosis without the need for risky, costly and often unnecessary surgery. veracyte consistently brings to bear evidence that is unprecedented in genomic tests, thereby changing today's clinical practice standards. we are making a difference in the lives of physicians and patients. we are doing something real. .
Veracyte Inc executives and other stock owners filed with the SEC include: